Company intelligence / Profile preview

LifeBond

Ownership: Private
Development stage: Commercial

Overview

LifeBond developed a proprietary hydrogel-based surgical sealant ("LifeSeal") designed to reduce postoperative complications such as staple-line leakage after gastrointestinal surgeries, including colorectal and bariatric procedures. The company also developed "LifeMesh," a self-fixating hernia mesh using the same core adhesive technology. Clinical studies demonstrated efficacy in reducing leaks, with pivotal trials supported by significant venture funding from major investors including Johnson & Johnson's JJDC arm.

Therapeutic areas: GastroenterologyHematology
Modalities: DeviceHydrogel-based drug delivery therapyBiologic
Industry: Surgical Medical Devices

Partnerships

Johnson & Johnson/JJDC investment arm participated in funding rounds

Beyond the preview

Go deeper on LifeBond.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LifeBond.

Explore the full profile